For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 3,134,810 | 2,395,471.5* | 3,110,752 | 2,699,991 |
| General and administrative | 2,266,110 | 6,984,093* | 2,618,679 | 2,744,545 |
| Total operating expenses | 5,400,920 | 9,379,564.5 | 5,729,431 | 5,444,536 |
| Loss from operations | -5,400,920 | -9,379,564.5* | -5,729,431 | -5,444,536 |
| Interest expense, net | -71,166 | -45,058.5* | -62,340 | -38,033 |
| Change in fair value of warrants | -25,831 | 4,622.5* | -64,959 | 21,410 |
| Merger transaction costs | - | - | - | 0 |
| Loss on issuance of commitment shares | - | - | - | 0 |
| Change in fair value of written call option derivative liabilities | - | - | - | 0 |
| Change in fair value of convertible promissory notes | - | - | - | 0 |
| Net loss | -5,446,255 | -9,429,245.5 | -5,726,812 | -5,503,979 |
| Basic EPS | -1.61 | 0.025 | -0.03 | -0.03 |
| Diluted EPS | -1.61 | 0.025 | -0.03 | -0.03 |
| Basic Average Shares | 3,486,215 | -370,376,517 | 196,028,784 | 184,307,169 |
| Diluted Average Shares | 3,486,215 | -370,376,517 | 196,028,784 | 184,307,169 |
Tevogen Bio Holdings Inc. (TVGN)
Tevogen Bio Holdings Inc. (TVGN)